Mounjaro vs. Zepbound: Same Drug, Two Labels — What Actually Differs (2026)

Type "Mounjaro vs Zepbound" into any search box and you're asking one of 2026's most-searched pharmaceutical questions — and one of its most misunderstood. The confusion-ending fact first: Mounjaro and Zepbound are the same drug. Both are tirzepatide, made by Eli Lilly, at the identical 2.5-through-15 mg weekly dose ladder, in the same KwikPen device. A milligram of one is a milligram of the other. Everything that actually differs — and plenty does — lives in the label, the coverage machinery, and the price programs attached to each name.

Why one molecule wears two names

Drug companies register separate brands for separate indications, and Lilly split tirzepatide cleanly: Mounjaro launched in 2022 with a type 2 diabetes indication, built on the SURPASS trial program (the largest A1C reductions ever recorded in that program's comparisons, plus the 2025 SURPASS-CVOT cardiovascular result against dulaglutide). Zepbound launched in late 2023 with the chronic weight management indication from the SURMOUNT program (20.9% average loss in SURMOUNT-1; the 20.2%-vs-13.7% head-to-head win over semaglutide in SURMOUNT-5), and added moderate-to-severe obstructive sleep apnea with obesity in December 2024. Same molecule, same pharmacology, same side-effect profile, same boxed warning and contraindications — different paperwork. And in American medicine, paperwork is destiny.

The coverage consequences of a label

Insurance systems don't cover molecules; they cover indications. If you have type 2 diabetes, Mounjaro is the on-label prescription, it flows through the diabetes benefit most plans have carried for years, prior authorization is comparatively routine, and the Mounjaro savings card (which requires a T2D diagnosis and commercial coverage) applies. If you're treating obesity without diabetes, Zepbound is the on-label drug: it's the name your plan's weight-management benefit (43% of large employers and counting), the OSA side door, and the new Medicare coverage all recognize — and the Zepbound savings card drops covered copays as low as $25. Cross the streams and things jam: plans routinely deny Mounjaro without documented diabetes, pharmacies flag off-label GLP-1 claims, and the savings cards each enforce their own indication. The practical rule is boring and absolute: let the diagnosis pick the name.

The self-pay gap nobody expects

Here is the difference that actually costs money. Zepbound has a cash program; Mounjaro effectively doesn't. Through LillyDirect — and, since March 2026, at retail pharmacies including Walmart — Zepbound self-pays at $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg), about $350 on TrumpRx, with the 45-day refill cadence guarding those tiers. Mounjaro's cash price remains its list price: north of $1,000 a month at retail, because Lilly built the self-pay architecture around the obesity brand, not the diabetes one. The absurd-sounding consequence is real: an uninsured patient with diabetes pays dramatically less for the identical medication if their clinician can appropriately prescribe the weight-management brand instead — a legitimate clinical judgment where obesity coexists, and a conversation worth having explicitly. (Compounded tirzepatide, which carries neither label, sits below both at a verified $215 floor — a separate product with separate caveats.)

Dosing, switching, and the non-differences

Because the drug is the drug, the clinical mechanics are interchangeable: the same 2.5 mg starter month, the same 2.5 mg steps at four-week-plus intervals, the same 10–15 mg maintenance zone, the same missed-dose (96-hour) and spacing (72-hour) rules from the dosing guide. A patient moved from Mounjaro to Zepbound (or back) for insurance reasons continues at the same dose the next week — no washout, no re-titration, nothing but a new prescription and, often, a new prior authorization. Side effects don't care which box the pen came in: the GI-dominant profile, the management playbook, the thyroid boxed warning, and the pregnancy and anesthesia rules are identical. Anyone selling you a tolerability difference between the two names is selling.

The decision tree, complete

Diabetes, insured: Mounjaro, through the diabetes benefit, with its savings card — the smoothest path in the whole class. Obesity or OSA, insured: Zepbound, through the weight benefit or the OSA door, savings card to $25, Medicare's ~$50 tier if eligible — the insurance guide maps the order of operations. No coverage: Zepbound's $299–$449 program is the only rational brand path regardless of your diagnosis conversation, benchmarked against the compounded market's $215 floor in the full comparison. Both conditions: you and your clinician get to choose the label that opens the better door — one of the few times American drug-pricing complexity cuts in the patient's favor. Whatever the name on the pen, you're getting the strongest approved obesity molecule on the market; the label is just the key, and now you know which locks each key fits.

Three buyers, worked to the dollar

The insured type 2 diabetic. Mounjaro through the diabetes benefit: typical covered copays $25–$100 depending on tier, savings card (T2D + commercial coverage required) pulling many to the floor — $300–$1,200/year for the class's strongest glycemic agent. Attempting Zepbound instead usually adds friction here, not savings: the weight benefit is the narrower door when a diabetes benefit is open. The insured non-diabetic treating obesity. Zepbound is the only workable name: weight-management benefit or OSA indication, prior auth with BMI documentation, savings card to $25, Medicare's ~$50 tier if eligible — while a Mounjaro claim without T2D documentation is a denial generator, full stop. The cash payer, either diagnosis. Zepbound's program is the whole game: $299–$449 by dose ($5,188 first titrated year; $5,388/maintenance year), ~$350 TrumpRx, versus Mounjaro's $12,000+ list-price year — with the compounded tirzepatide market underneath both at $215–$597 all-in for the label-free molecule. The lesson across all three: in this pair, the paperwork is the price.

The stocking quirk and the naming trap

Two field notes finish the picture. Pharmacy stocking follows the split: retail counters increasingly carry both, but insurance rejections at pickup are overwhelmingly name-indication mismatches — the fix is a phone call to swap the script, not a new drug. And internationally the naming logic breaks entirely: in many markets Mounjaro is the weight-loss brand (Zepbound doesn't exist there), which seeds endless online confusion — dosing threads, price claims, coupon rumors — that doesn't transfer to U.S. rules. When reading anything about "Mounjaro for weight loss," check the flag before the facts.

The compounded footnote both labels share

One more clarity the two-name confusion obscures: compounded tirzepatide carries neither label. It isn't Mounjaro, isn't Zepbound, isn't FDA-approved as anything — it's the molecule, prepared by a pharmacy under the contested post-shortage rules, priced from $215 verified all-in with every caveat the legal guide documents. Sites selling "compounded Mounjaro" or "generic Zepbound" are misusing both trademarks — a red flag our legitimacy checklist weights heavily, since programs precise about the law tend to be precise about the pharmacy too. The clean mental model: three products, one molecule — Mounjaro (diabetes label), Zepbound (obesity/OSA label), and compounded tirzepatide (no label, different rules, different price) — and every price claim you read belongs to exactly one of the three.

SURPASS vs. SURMOUNT: what each name's evidence actually proved

The two labels rest on two of the largest trial programs in metabolic medicine, and knowing what each demonstrated clarifies why the paperwork splits the way it does. SURPASS (Mounjaro's file) ran tirzepatide through type 2 diabetes: head-to-head A1C superiority over semaglutide 1 mg (SURPASS-2), over basal insulins, and over placebo across the program — reductions in the 2.0–2.5 point range that redefined "powerful" in glycemic control — capped by 2025's SURPASS-CVOT, which matched-to-beat an active cardioprotective comparator (dulaglutide, hazard ratio ~0.92) in high-risk diabetes. Weight loss appeared throughout, but as a secondary endpoint at diabetes-typical magnitudes. SURMOUNT (Zepbound's file) ran the same molecule through obesity: 20.9% average loss in SURMOUNT-1, superiority over semaglutide 2.4 mg in the 20.2%-vs-13.7% head-to-head (SURMOUNT-5), maintenance durability in SURMOUNT-4 — and the OSA program that produced December 2024's sleep-apnea indication. Same pharmacology, two evidentiary portfolios: one proves the drug treats diabetes exceptionally (with cardiovascular safety in that population), the other proves it treats obesity and its complications exceptionally. Insurers read the portfolios literally — which is the entire reason this article exists — and so should patients weighing what their diagnosis entitles them to: the SURMOUNT explainer unpacks the obesity file trial by trial.

The compounded footnote both names share

One more identity the two brands can't escape: the compounded tirzepatide market tracks the molecule, not the label — so every compounded program is, functionally, competing with both names at once, from a verified floor of $215 that undercuts Zepbound's self-pay tiers and demolishes Mounjaro's cash list price. The label logic of this article dissolves entirely there: compounded product carries no indication, no savings-card machinery, and no coverage pathway — just the active pharmaceutical ingredient, a prescriber's judgment, and the diligence questions that substitute for FDA review. Which clarifies the full 2026 decision tree one last time: coverage available → the brand your diagnosis matches, at $25–$50; no coverage, brand preferred → Zepbound's tiers regardless of diagnosis; no coverage, price decisive → the compounded market with eyes open. Three doors, one molecule behind all of them.